ANXA2 expression in African American triple-negative breast cancer patients

Lee D. Gibbs; Pankaj Chaudhary; Kelsey Mansheim; Richard J. Hare; Rebecca A. Mantsch; Jamboor K. Vishwanatha

doi:10.1007/s10549-018-5030-5

ANXA2 expression in African American triple-negative breast cancer patients

Lee D. Gibbs, Pankaj Chaudhary, Kelsey Mansheim, Richard J. Hare, Rebecca A. Mantsch, Jamboor K. Vishwanatha

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Purpose: Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBC patients and clinical outcome. Methods: We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study. Results: In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in other breast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, human epidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBC patients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBC patients (CISH average score = 1.1 ± 0.4069). Conclusion: AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.

Original language	English
Pages (from-to)	113-120
Number of pages	8
Journal	Breast Cancer Research and Treatment
Volume	174
Issue number	1
DOIs	https://doi.org/10.1007/s10549-018-5030-5
State	Published - 28 Feb 2019

Keywords

African American
Annexin A2
Biomarker
Prognosis
Triple-negative breast cancer

Access to Document

10.1007/s10549-018-5030-5

Cite this

@article{54849c27a3bb4f31ac23dc110288d456,

title = "ANXA2 expression in African American triple-negative breast cancer patients",

abstract = "Purpose: Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBC patients and clinical outcome. Methods: We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study. Results: In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in other breast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, human epidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBC patients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBC patients (CISH average score = 1.1 ± 0.4069). Conclusion: AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.",

keywords = "African American, Annexin A2, Biomarker, Prognosis, Triple-negative breast cancer",

author = "Gibbs, {Lee D.} and Pankaj Chaudhary and Kelsey Mansheim and Hare, {Richard J.} and Mantsch, {Rebecca A.} and Vishwanatha, {Jamboor K.}",

note = "Funding Information: Funding Research reported in this publication was supported by of the National Institutes of Health under the National Cancer Institute Award Number R01CA220273 and National Institute on Minority Health and Health Disparities Award Number P20MD006882. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = feb,

day = "28",

doi = "10.1007/s10549-018-5030-5",

language = "English",

volume = "174",

pages = "113--120",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - ANXA2 expression in African American triple-negative breast cancer patients

AU - Gibbs, Lee D.

AU - Chaudhary, Pankaj

AU - Mansheim, Kelsey

AU - Hare, Richard J.

AU - Mantsch, Rebecca A.

AU - Vishwanatha, Jamboor K.

N1 - Funding Information: Funding Research reported in this publication was supported by of the National Institutes of Health under the National Cancer Institute Award Number R01CA220273 and National Institute on Minority Health and Health Disparities Award Number P20MD006882. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2019/2/28

Y1 - 2019/2/28

N2 - Purpose: Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBC patients and clinical outcome. Methods: We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study. Results: In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in other breast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, human epidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBC patients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBC patients (CISH average score = 1.1 ± 0.4069). Conclusion: AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.

AB - Purpose: Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBC patients and clinical outcome. Methods: We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study. Results: In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in other breast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, human epidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBC patients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBC patients (CISH average score = 1.1 ± 0.4069). Conclusion: AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.

KW - African American

KW - Annexin A2

KW - Biomarker

KW - Prognosis

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85057333711&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-5030-5

DO - 10.1007/s10549-018-5030-5

M3 - Article

C2 - 30478786

AN - SCOPUS:85057333711

VL - 174

SP - 113

EP - 120

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -

ANXA2 expression in African American triple-negative breast cancer patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this